Patents
US 10167471 B2: Inhibition of PCSK9 through RNAI
- Granted
- 2019-01-01
- Filed
- 2016-10-06 application 15286948
- Type
- Utility · 11 claims
- Elsewhere
- Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗
Abstract
The invention relates to various PCSK9 RNAi constructs with gene silencing activities, and uses thereof. The construct has a double-stranded region of 19-49 nucleotides, preferably 25, 26, or 27 nucleotides, and preferably blunt-ended. The construct has selective minimal modifications to confer an optimal balance of biological activity, toxicity, stability, and target gene specificity. The sense strand may be modified such that the construct is not cleaved by Dicer or other RNAse III, and the entire length of the antisense strand is loaded into RISC In addition, the antisense strand may also be modified by 2′-O-methyl groups at the 2nd 5′-end nucleotide to greatly reduce off-target silencing. The constructs of the invention largely avoid the interferon response and sequence-independent apoptosis in mammalian cells, exhibits better serum stability, and enhanced target specificity.
Source: PVGPATDIS, file of 2026-04-10 (ipg190101.xml).
Assignees
| Assignee | Type | Place | Also on furp.org | Source |
|---|---|---|---|---|
| RXi Pharmaceuticals Corporation 17 patents | US company or organization | Marlborough, MA | PVGPATDIS, file of 2026-04-10 |
Inventors
| Inventor | Place | Patents | Person page | Source |
|---|---|---|---|---|
| Joanne Kamens | Newton, MA | 30 | PVGPATDIS, file of 2026-04-10 | |
| Anastasia Khvorova | Westborough, MA | 193 | PVGPATDIS, file of 2026-04-10 |
CPC categories
| Subclass | Category | First group | Source |
|---|---|---|---|
| C12N | Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media | C12N15/1137 | PVGPATDIS, file of 2026-04-10 |
| C12Y | Enzymes | C12Y304/21112 | PVGPATDIS, file of 2026-04-10 |
Cooperative Patent Classification, as currently assigned (one row per subclass).
Assignments and security interests
| Recorded | What | From | To | Reel/frame | Source |
|---|---|---|---|---|---|
| 2018-12-07 | Name change Change of name | RXI PHARMACEUTICALS CORPORATION signed 2018-11-14 | PHIO PHARMACEUTICALS CORP. MARLBOROUGH, MA | 48380/9 | PASDL, file of 2026-10-15 |
| 2016-12-19 | Assignment Assignment of assignor's interest | KAMENS, JOANNE signed 2012-08-06 KHVOROVA, ANASTASIA signed 2012-08-07 | RXI PHARMACEUTICALS CORPORATION MARLBOROUGH, MA | 40656/467 | ECORSEXC, file of 2026-09-25 |
Documents recorded with the USPTO Assignment Recordation Branch that list this patent. A security interest is a lender’s claim on the patent as collateral; a release ends it.
USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.